Arcutis Biotherapeutics (ARQT) said Sunday its preliminary fiscal Q4 revenue is expected to increase by about 366% to $63 million, driven by the demand for Zoryve, a skin disease treatment.
Analysts surveyed by FactSet expect revenue of $56.5 million.
Meanwhile, full-year product revenue is expected to be about $160 million, up by about 449% from a year earlier.
As of Dec. 31, preliminary cash, cash equivalents, restricted cash and marketable securities are expected to be about $229 million.
The company is set to report its fiscal Q4 results on Feb. 25.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.